Me (ME), the company that popularized consumer genetic testing, announced Tuesday that it is once again exploring “strategic ...

A pioneer in genetic heritage services, 23andMe has seen much of its share price wiped out in the past year as it struggles ...

By the 2023 fiscal year, 23andMe had reported a net loss of $312 million and its individual share price has plummeted a ...

Me (ME) forms special board committee to explore strategic alternatives, including sale, restructuring, or business ...

Embattled genetic testing company 23andMe said on Tuesday that it's started exploring strategic alternatives for a second ...

23andMe has been testing the waters for a buyer for Lemonaid Health, the virtual-care business it bought in 2021 for $400 million in cash and stock, people with knowledge of the efforts told BI.

23andMe's stock plummeted after a 2023 data breach exposed millions of customer accounts. The struggling genetic-testing company 23andMe has been quietly exploring a possible sale of its ...

Holding released a new polygenic risk score report on the genetics of osteoporosis for 23andMe+ Premium members. The report ...

Company Notes Continued Concerns Regarding Liquidity and Consideration of Potential Ways to Address Operational and Financial ...

23andMe has no debt on its balance sheet ... expenses (benefit), depreciation and amortization, impairment charges, stock-based compensation expense, and other items that are considered unusual ...

23andMe Holding Co. has launched a new polygenic risk score (PRS) report for osteoporosis, available to 23andMe+ Premium members. This report assesses an individual's genetic likelihood of ...